Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature.

OBJECTIVES Information on the health care costs associated with nonadherence to treatments for diabetes is both limited and inconsistent. We reviewed and critically appraised the literature to identify the main methodological issues that might explain differences among reports in the relationship of nonadherence and costs in patients with diabetes. METHODS Two investigators reviewed Medline, EMBASE, Cochrane library and CINAHL and studies with information on costs by level of adherence in patients with diabetes published between January 1, 1997 and September 30th 2007 were included. RESULTS A total of 209 studies were identified and ten fulfilled the inclusion criteria. All included studies analyzed claims data and 70% were based on non-Medicaid and non-Medicare databases. Low medication possession ratios were associated with higher costs. Important differences were found in the ICD-9/ICD-9 CM codes used to identify patients and their diagnoses, data sources, analytic window period, definitions of adherence measures, skewness in cost data and associated statistical issues, adjustment of costs for inflation, adjustment for confounders, clinical outcomes and costs. CONCLUSIONS Important variation among cost estimates was evident, even within studies of the same population. Readers should be cautious when comparing estimated coefficients from various studies because methodological issues might explain differences in the results of costs of nonadherence in diabetes. This is particularly important when estimates are used as inputs to pharmacoeconomic models.

[1]  K. Secnik,et al.  Relationship of Glycemic Control to Total Diabetes-Related Costs for Managed Care Health Plan Members With Type 2 Diabetes , 2005, Journal of managed care pharmacy : JMCP.

[2]  V. Basevi Standards of medical care in diabetes--2007. , 2009, Diabetes care.

[3]  A. Classification,et al.  Standards of Medical Care in Diabetes—2009 , 2009, Diabetes Care.

[4]  Yelena Rozenfeld,et al.  Oral antidiabetic medication adherence and glycemic control in managed care. , 2008, The American journal of managed care.

[5]  Taghreed Adam,et al.  The burden and costs of chronic diseases in low-income and middle-income countries , 2007, The Lancet.

[6]  S. Hahn,et al.  Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). , 2007, Investigative ophthalmology & visual science.

[7]  J. Cramer,et al.  Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  C. Pashos,et al.  Health Outcomes and Economic Impact of Therapy Conversion to a Biphasic Insulin Analog Pen Among Privately Insured Patients with Type 2 Diabetes Mellitus , 2007, Pharmacotherapy.

[9]  S. Balu Incremental treatment expenditure of diabetes in the United States. , 2007, Managed care interface.

[10]  A. Palmer,et al.  Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: A modeling study of cost-effectiveness in the United States , 2007, Advances in therapy.

[11]  T. Peters,et al.  Cigarette smoking and adherence to antihypertensive medication in patients from primary care , 2007, The European journal of general practice.

[12]  S. Majumdar,et al.  Health Care Use and Costs in the Decade After Identification of Type 1 and Type 2 Diabetes , 2006, Diabetes Care.

[13]  C. Pashos,et al.  Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. , 2006, Clinical therapeutics.

[14]  J. Steiner,et al.  A Systematic Review of the Literature , 2019, HIV/AIDS and Adolescents.

[15]  P. Phillips,et al.  Gestational diabetes--worth finding and actively treating. , 2006, Australian family physician.

[16]  F. Camacho,et al.  Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. , 2006, Clinical therapeutics.

[17]  C. Pashos,et al.  Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. , 2006, Managed care interface.

[18]  Marsha A Raebel,et al.  Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures , 2006, The Annals of pharmacotherapy.

[19]  M. Cheang,et al.  Validity of a Prescription Claims Database to Estimate Medication Adherence in Older Persons , 2006, Medical care.

[20]  B. Bolinder,et al.  Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[21]  S. Iyer,et al.  Utilization and Costs for Compliant Patients Initiating Therapy With Pioglitazone or Rosiglitazone Versus Insulin in a Medicaid Fee-for-Service Population , 2006, Journal of managed care pharmacy : JMCP.

[22]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[23]  P. Griner Health care costs. , 2005, Annals of internal medicine.

[24]  A. Lippman Adherence to medication. , 2005, The New England journal of medicine.

[25]  R. Verbrugge,et al.  Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.

[26]  H. Gerstein Glycosylated Hemoglobin: Finally Ready for Prime Time as a Cardiovascular Risk Factor , 2004, Annals of Internal Medicine.

[27]  Neil R. Powe,et al.  Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.

[28]  F. Camacho,et al.  Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis , 2004, Current medical research and opinion.

[29]  J. Cramer A systematic review of adherence with medications for diabetes. , 2004, Diabetes care.

[30]  Carol M Mangione,et al.  Diabetes Care Quality in the Veterans Affairs Health Care System and Commercial Managed Care: The TRIAD Study , 2004, Annals of Internal Medicine.

[31]  J. Cramer A Systematic Review of Adherence With Medications for Diabetes , 2004 .

[32]  A. Vanderplas,et al.  The Costs of Non-Adherence to Oral Antihyperglycemic Medication in Individuals with Diabetes Mellitus and Concomitant Diabetes Mellitus and Cardiovascular Disease in a Managed Care Environment , 2004 .

[33]  N. Horton,et al.  Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. , 2004, Addiction.

[34]  R. Tamblyn,et al.  Validation of diagnostic codes within medical services claims. , 2004, Journal of clinical epidemiology.

[35]  D. Share,et al.  Costs and utilization associated with pharmaceutical adherence in a diabetic population. , 2004, The American journal of managed care.

[36]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[37]  F. Camacho,et al.  Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. , 2003, Clinical therapeutics.

[38]  R Legood,et al.  The impact of diabetes‐related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65) , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[39]  C. Sherbourne,et al.  Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. , 2003, The American journal of medicine.

[40]  J. Caro,et al.  Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. , 2002, Clinical therapeutics.

[41]  M. Engelgau,et al.  A Diabetes Report Card for the United States: Quality of Care in the 1990s , 2002, Annals of Internal Medicine.

[42]  A Haycox,et al.  The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. , 2001, Health economics.

[43]  S. Lewis,et al.  Impact of rural hospital closures in Saskatchewan, Canada. , 2001, Social science & medicine.

[44]  Joseph Conigliaro,et al.  Problem drinking and medication adherence among persons with HIV infection , 2001, Journal of General Internal Medicine.

[45]  E H Wagner,et al.  Effect of improved glycemic control on health care costs and utilization. , 2001, JAMA.

[46]  J. Apelqvist,et al.  The inpatient care of patients with diabetes mellitus and foot ulcers. A validation study of the correspondence between medical records and the Swedish Inpatient Registry with the consequences for cost estimations , 2000, Journal of Internal Medicine.

[47]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[48]  E. Wagner,et al.  The use of automated data to identify complications and comorbidities of diabetes: a validation study. , 1999, Journal of clinical epidemiology.

[49]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[50]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[51]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[52]  Femida Gwadry-Sridhar,et al.  A checklist for medication compliance and persistence studies using retrospective databases. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[53]  F. Camacho,et al.  Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. , 2007, Clinical therapeutics.

[54]  S. Majumdar,et al.  Health care costs and mortality for Canadian urban and rural patients with diabetes: population-based trends from 1993-2001. , 2007, Clinical therapeutics.

[55]  David B. Hogan,et al.  Medication Nonadherence and Subsequent Risk of Hospitalisation and Mortality among Older Adults , 2006, Drugs & aging.

[56]  Paula Williamson,et al.  A comparison of multivariable regression models to analyse cost data. , 2006, Journal of evaluation in clinical practice.

[57]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[58]  E. van Doorslaer,et al.  Statistical analysis of cost outcomes in a randomized controlled clinical trial. , 1994, Health economics.

[59]  M. de Luise,et al.  Diabetes mellitus. , 1993, The Medical journal of Australia.

[60]  S. Finkler The distinction between cost and charges. , 1982, Annals of internal medicine.